ATAI Life Sciences AG's Form 4 filing
IntelGenx Technologies Corp. (IGXT) · filed Sep 5, 2023
- Accession no.
- 0000950170-23-046540
- Filed
- Sep 5, 2023, 9:00 PM ET
- Trade date
- Aug 31, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| ATAI Life Sciences AGCIK 0001776242 | 10% Owner |
| ATAI Life Sciences N.V.CIK 0001840904 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000.
Referenced by the price of 2 transactions in Table II.